Biotech entity
Every one of those 1 sits in a single category, pharma. Tecentriq SC (atezolizumab/hyaluronidase) is most often covered alongside DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Tecentriq SC (atezolizumab/hyaluronidase), all published on August 12, 2026.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Tecentriq SC (atezolizumab/hyaluronidase) is most often covered alongside DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Tecentriq SC (atezolizumab/hyaluronidase), all published on August 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tecentriq SC (atezolizumab/hyaluronidase). Shared-story counts are live from our verified record — not editorial picks.
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
Tecentriq SC (atezolizumab/hyaluronidase) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
